These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33763345)

  • 21. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
    Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
    ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Unseld M; Drimmel M; Siebenhüner A; Gleiss A; Bianconi D; Kieler M; Scheithauer W; Winder T; Prager GW
    Clin Colorectal Cancer; 2018 Dec; 17(4):274-279. PubMed ID: 30042010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication.
    Nakanishi R; Kitao H; Kiniwa M; Morodomi Y; Iimori M; Kurashige J; Sugiyama M; Nakashima Y; Saeki H; Oki E; Maehara Y
    Sci Rep; 2017 Dec; 7(1):16969. PubMed ID: 29208954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme.
    Sforza V; Martinelli E; Cardone C; Martini G; Napolitano S; Vitiello PP; Vitale P; Zanaletti N; Reginelli A; Bisceglie MD; Latiano TP; Bochicchio AM; Cecere F; Selvaggi F; Ciardiello F; Troiani T
    ESMO Open; 2017; 2(4):e000229. PubMed ID: 29018575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Clinical Experience with Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: The ROS Study.
    García-Alfonso P; Muñoz A; Jiménez-Castro J; Jiménez-Fonseca P; Pericay C; Longo-Muñoz F; Reyna-Fortes C; Argilés-Martínez G; González-Astorga B; Gómez-Reina MJ; Ruiz-Casado A; Rodríguez-Salas N; López-López R; Carmona-Bayonas A; Conde-Herrero V; Aranda E; On Behalf Of The Ros Study Group
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study.
    Xu J; Kim TW; Shen L; Sriuranpong V; Pan H; Xu R; Guo W; Han SW; Liu T; Park YS; Shi C; Bai Y; Bi F; Ahn JB; Qin S; Li Q; Wu C; Ma D; Lin D; Li J
    J Clin Oncol; 2018 Feb; 36(4):350-358. PubMed ID: 29215955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Regorafenib and Trifluridine and Tipiracil Hydrochloride Can Potentially Improve the Survival Time for Patients with Advanced or Recurrent Colorectal Cancer].
    Oki M; Nakamura A; Shinamura N; Sugaya T; Takagi K; Sugaya M
    Gan To Kagaku Ryoho; 2018 Sep; 45(9):1297-1303. PubMed ID: 30237371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Trifluridine/Tipiracil Monotherapy in Clinical Practice for Patients With Metastatic Colorectal Cancer: Experience at a Single Institution.
    Kotani D; Shitara K; Kawazoe A; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Doi T; Ohtsu A; Yoshino T
    Clin Colorectal Cancer; 2016 Sep; 15(3):e109-15. PubMed ID: 26723516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
    Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
    Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis.
    Signorelli C; Chilelli MG; Giannarelli D; Basso M; Calegari MA; Anghelone A; Lucchetti J; Minelli A; Angotti L; Zurlo IV; Schirripa M; Morelli C; Dell'Aquila E; Cosimati A; Gemma D; Ribelli M; Emiliani A; Corsi DC; Arrivi G; Mazzuca F; Zoratto F; Morandi MG; Santamaria F; Saltarelli R; Ruggeri EM
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136304
    [No Abstract]   [Full Text] [Related]  

  • 31. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study.
    Kawakami T; Masuishi T; Kawamoto Y; Go H; Kato K; Kumanishi R; Sawada K; Yuki S; Yamamoto K; Komatsu Y; Muro K; Fushiki K; Shirasu H; Yamazaki K
    Cancer Med; 2022 Jun; 11(11):2184-2192. PubMed ID: 35182029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.
    Fernandez Montes A; Vazquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; de la Cámara Gómez J; Méndez Méndez JC; Salgado Fernández M; Candamio Folgar S; Reboredo López M; Carmona Campos M; Gallardo Martín E; Jorge Fernández M; Pellón Augusto ML; París Bouzas L; García Gómez J
    Clin Transl Oncol; 2020 Mar; 22(3):351-359. PubMed ID: 31073972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 35. The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC.
    Prager G; Köhne CH; O'Connor JM; Rivera F; Santini D; Wasan H; Phelip JM
    Curr Oncol; 2021 Jun; 28(3):2097-2106. PubMed ID: 34199694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
    Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
    Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer.
    Antoniotti C; Marmorino F; Boccaccino A; Martini S; Antista M; Rossini D; Zuco V; Prisciandaro M; Conca V; Zucchelli G; Borelli B; Cosentino P; Germani MM; Bosco MF; Carullo M; Vetere G; Moretto R; Giordano M; Masi G; Pietrantonio F; Zaffaroni N; Cremolini C
    Eur J Cancer; 2022 Apr; 165():116-124. PubMed ID: 35231767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer.
    Huemer F; Schlintl V; Hecht S; Hackl H; Melchardt T; Rinnerthaler G; Greil R; Weiss L
    Clin Colorectal Cancer; 2019 Jun; 18(2):159-166.e3. PubMed ID: 31060856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy.
    Huemer F; Piringer G; Schlintl V; Hackl H; Rinnerthaler G; Thaler J; Greil R; Weiss L
    Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33007814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer.
    Kimura M; Usami E; Iwai M; Go M; Teramachi H; Yoshimura T
    Mol Clin Oncol; 2016 Nov; 5(5):635-640. PubMed ID: 27900102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.